*For medical professionals only
Clinical information, 1s reach
Gout is a common metabolic disorder directly associated with hyperuricemia due to disorders of purine metabolism and/or decreased uric acid excretion. Gout can also be complicated by renal lesions, and in severe cases, joint destruction and renal function damage may occur [1].
Studies by Sriranganathan et al. have shown that allopurinol, benzbromarone, allopurinol combined with benzbromomarone, febuxex, and other drugs can reduce uric acid and reduce tophi [2].
The results of two clinical trials using allopurinol for chronic kidney disease (CKD) showed no benefit and may increase their risk of death. It is unclear whether this risk may occur in patients with gout and chronic kidney disease [3-4].
Source: Screenshot of literature
Recently, Jie Wei et al. published a paper in the annals of internal medicine, Ann Intern Med, which aimed to evaluate the relationship between allopurinol and increasing allopurinol doses on all-cause mortality and target serum uric acid in patients with gout and chronic kidney disease [5]. Let's take a look at today's newsletter!
Want to see more of the previous issues of "Top Essentials"?
Go to the "Clinical Decision Assistant" service number to see!